MedTrace Logo

Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)

NCT02262364 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2019-02-15

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the safety of a single injection of APS.

Conditions

  • Osteoarthritis, Knee

Interventions

BIOLOGICAL

APS

See above

Sponsors & Collaborators

  • Biomet Biologics, LLC

    collaborator INDUSTRY

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Mark Klaassen · OSMC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02262364 on ClinicalTrials.gov